Adrian Haigh Sells 22,222 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of the stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $9.34, for a total value of $207,553.48. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Adrian Haigh also recently made the following trade(s):

• On Monday, April 22nd, Adrian Haigh sold 22,223 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.32, for a total value of $207,118.36.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total value of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.30, for a total value of $228,886.60.

Fennec Pharmaceuticals Stock Performance

Shares of FENC stock opened at $9.07 on Thursday. The firm has a market cap of $245.80 million, a P/E ratio of -14.87 and a beta of 0.38. Fennec Pharmaceuticals Inc has a fifty-two week low of $6.30 and a fifty-two week high of $11.92. The business’s 50 day moving average price is $10.05 and its 200-day moving average price is $9.42.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $9.74 million during the quarter, compared to analysts’ expectations of $9.47 million. As a group, equities analysts predict that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current year.

Wall Street Analyst Weigh In

FENC has been the topic of several recent research reports. Craig Hallum raised their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. HC Wainwright raised their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, April 4th. Finally, Wedbush restated an “outperform” rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a research report on Monday, March 18th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in shares of Fennec Pharmaceuticals by 107.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after purchasing an additional 1,578 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of Fennec Pharmaceuticals in the 3rd quarter valued at approximately $50,000. Jump Financial LLC purchased a new position in shares of Fennec Pharmaceuticals in the 4th quarter valued at approximately $158,000. Eudaimonia Advisors LLC lifted its stake in shares of Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock valued at $367,000 after purchasing an additional 15,556 shares during the period. Finally, Hartford Financial Management Inc. lifted its stake in shares of Fennec Pharmaceuticals by 4.4% in the 4th quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock valued at $531,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.